Status:
COMPLETED
Effects of ONO-2506PO in Patients With Alzheimer's Disease
Lead Sponsor:
Ono Pharma USA Inc
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50-90 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.
Eligibility Criteria
Inclusion
- Diagnosis of probable Alzheimer's Disease using NINCDS/ADRDA criteria
- Standardized MMSE Score of 13 to 24 points (inclusive)
- Modified Hachinski score equal or less than 4
Exclusion
- Serious systemic disease that may preclude survival to study completion
- Other illnesses that may include dementive features
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
647 Patients enrolled
Trial Details
Trial ID
NCT00083421
Start Date
June 1 2004
End Date
July 1 2007
Last Update
June 13 2012
Active Locations (87)
Enter a location and click search to find clinical trials sorted by distance.
1
Kirkland Clinic
Birmingham, Alabama, United States, 35233
2
Alzheimers Disease Research Center
Birmingham, Alabama, United States, 35294
3
Pivotal Research Center
Mesa, Arizona, United States, 85210
4
HOPE Research Institute
Phoenix, Arizona, United States, 85032